drugset / Trial / NCT04680767

A Study of LY3502970 in Healthy Male Participants

NCT04680767

Phase 1 Completed 6 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelBasic science

Summary

The main purpose of this study is to measure how much of the study drug gets into the bloodstream and how long it takes the body to eliminate it. This study will involve a single dose of ¹⁴C radiolabelled LY3502970. This means that a radioactive substance will be incorporated into the study drug. The purposes are to investigate the study drug and its breakdown products and to find out how much of these pass from blood into urine and feces. The study will last up to 8 weeks (maximum).

Timeline

Start
2021-03-29
Primary completion
2021-07-03
Completion
2021-07-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Orforglipron Small molecule 3 mg Oral

Indications

No indication recorded.